# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Florence Griffith Joyner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML033-SYN-TD
- Date: 1996-05-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Vanterpool, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three weeks on levetiracetam; neurosurgical opinion; SUDEP and safety counseling. **S**

## History of present illness

Ms. Griffith Joyner returns three weeks after starting levetiracetam. She has taken every dose. In the first ten days she felt short-tempered and more tired than usual after training; both are easing. She has had no seizure or spell. The neurosurgeon saw her last week and offered complete removal of the cavernous malformation with its hemosiderin rim through a left frontal craniotomy; she has chosen surgery, booked in three weeks. She wears the detection watch at night. She has not driven. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Levetiracetam | Every dose taken; irritability and tiredness easing |
| Seizures | None since the flight |
| Neurosurgery | Lesionectomy offered and chosen; booked in three weeks |
| Safety | Detection watch at night; not driving |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | More tired than usual after training, improving |
| Neurological | Negative | No seizures, spells, headache or dizziness |
| Psychiatric | Positive | Short-tempered in the first ten days, easing; sleep normal; PHQ-9 6; no thoughts of self-harm |
| Musculoskeletal | Negative | Training without injury |

4 systems reviewed. **S**

## Current medications

- Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily **S**
- Folic acid 0.4 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 114/72 mmHg; pulse 60 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 60.8 kg; BMI 21 kg/m². All vital signs are synthetic.

PHQ-9: 6. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 60.8 kg; blood pressure 114/72, pulse 60 |
| Neurological | Alert; speech, strength, coordination and gait normal |
| Psychiatric | Calm and engaged; describes the irritability with insight |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Focal epilepsy with structural cause** (G40.209). No seizure on levetiracetam. The irritability and tiredness are known effects of levetiracetam and are settling; PHQ-9 6 without low mood or thoughts of self-harm. Continue the same dose. The SUDEP discussion deferred at the last visit was held today. **S**
   - Continue levetiracetam 500 mg twice daily.
   - Call if irritability worsens or low mood appears: switching to lamotrigine is an option.
   - Continue the seizure diary, detection watch and safety plan.
2. **Solitary cerebral cavernous malformation, left orbitofrontal** (Q28.3). She chose lesionectomy after hearing the chance of freedom from seizures, the small risks of the operation, and the option of medication alone. **S**
   - Craniotomy in three weeks; continue levetiracetam through and after surgery.
   - No training for two weeks after surgery.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Mood and behavior on levetiracetam (PHQ-9) | Before starting and at each visit | Completed today | PHQ-9 6, from 3: irritability and tiredness on levetiracetam, easing; no thoughts of self-harm |
| Self-management | Seizure diary and adherence | Each visit | Completed today | No seizure; every dose taken |
| Referral | Neurosurgical evaluation of an epileptogenic cavernous malformation | When a cavernous malformation causes epilepsy | Up to date | Seen last week; lesionectomy chosen and booked |
| Self-management | SUDEP counseling | At diagnosis of epilepsy | Completed today | Discussed today, three weeks after the diagnosis (deviation recorded at the last visit): what SUDEP is, that tonic-clonic seizures are the main risk factor, and that the best protection is no tonic-clonic seizures, with every dose taken, regular sleep and little alcohol; nocturnal supervision or detection. No harm from the delay: no seizure in the interval. Corrective action: SUDEP added to the clinic's checklist for every new diagnosis of epilepsy |
| Self-management | Nocturnal seizure detection | When seizures may occur in sleep | Completed today | Wrist-worn detection watch worn every night, alerting a contact she chose |
| Self-management | Driving restriction and the California physician report | From the first seizure until cleared | Up to date | Not driving |
| Self-management | Seizure safety: water, heights, sleep and first aid | At diagnosis and each visit | Completed today | Reviewed; she follows the plan |
| Medication safety | Folic acid and contraception | Each visit | Completed today | Folic acid taken daily; no pregnancy planned |

## Goal progress

- EEG and MRI with susceptibility-weighted imaging within one week, and an epilepsy consultation within two weeks. Outcome by 1996-05-05: EEG in two days, MRI in six, consultation at two weeks. **S**
- No further seizures on an antiseizure medication she tolerates. In progress; target 1996-10-20. **S**
- Neurosurgical evaluation of the cavernous malformation and a shared decision about lesionectomy within two months. In progress; target 1996-07-21. **S**
- Safety plan in place: no driving until cleared, water and height safety, SUDEP discussion, and a nocturnal seizure detection plan. Outcome by 1996-05-27: Driving stopped and reported as California requires; SUDEP discussed (one visit late, recorded as a deviation); detection watch in use. **S**
- Graded return to full sprint training within four months of surgery. In progress; target 1996-10-20. **S**

## Guideline basis

- Krumholz A, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults. Neurology 2015;84(16):1705-1713 (PMID 25901057) (2015), American Academy of Neurology and American Epilepsy Society
- Fisher RS, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55(4):475-482 (PMID 24730690) (2014), International League Against Epilepsy
- Akers A, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017;80(5):665-680 (PMID 28387823) (2017), Angioma Alliance (Neurosurgery)
- Harden C, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors. Neurology 2017;88(17):1674-1680 (PMID 28438841) (2017), American Academy of Neurology and American Epilepsy Society
- Pack AM, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology 2024;102(11):e209279 (PMID 38748979) (2024), American Academy of Neurology, American Epilepsy Society and Society for Maternal-Fetal Medicine
- Beniczky S, et al. Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology. Epilepsia 2021;62(3):632-646 (PMID 33666944) (2021), International League Against Epilepsy and International Federation of Clinical Neurophysiology
- Governor's message returning Senate Bill 357 without signature (physician reporting of disorders characterized by lapses of consciousness remains mandatory under Health and Safety Code section 103900) (2024), Office of the Governor of California
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Lesionectomy in three weeks. Primary care review about five weeks after surgery. Call at once for another seizure, worsening mood, or any thoughts of self-harm. **S**
- Next scheduled visit 1996-07-21: five weeks after lesionectomy: recovery, seizure control, return to training. **S**
